---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Special populations"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Special populations. Topics: Pediatric patients: trial enrollment limited to adults, Older adults: phase 1 age range, Renal impairment: exclusion from trials, Hepatic impairment: exclusion from trials, and 2 further topics. 6 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/special-populations"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Pediatric patients: trial enrollment limited to adults

> “Age ≥18 years at the time of signing informed consent.”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

<a id="topic-2.1.2.8-2"></a>

### Older adults: phase 1 age range

> “Male and female adults 18 to 55 years old”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-3"></a>

### Renal impairment: exclusion from trials

> “Any clinically significant renal disease”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “Estimated creatinine clearance <60 mL/min or serum creatinine > 1.5-fold upper limit of normal.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-4"></a>

### Hepatic impairment: exclusion from trials

> “Any clinically significant hepatic disease”

Source: [ClinicalTrials.gov NCT06960213](https://clinicaltrials.gov/study/NCT06960213)

> “History of liver disease, Gilbert's syndrome, or abnormal liver function test”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-5"></a>

### Pregnancy and lactation: exclusion from the phase 1/2 study

> “Pregnancy, intent to become pregnant during the course of the study, or lactating women”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-2.1.2.8-6"></a>

### Pregnancy and fertility: nonclinical reproductive studies

> “Reproductive and developmental studies in rabbits showed no drug-related effects on fertility or embryo-fetal development.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
